Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.
Authors:
Open Access
- 1 August 1994
- journal article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 180 (2) , 595-606
Abstract
The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD65) is a major autoantigen in two human diseases that affect its principal sites of expression. Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD65. Anti-GAD65 autoantibodies in IDDM are predominantly directed to conformational epitopes. Here we report the characterization of humoral autoimmune responses to GAD65 in 35 SMS patients, of whom 13 (37%) also had IDDM. All SMS patients immunoprecipitated native GAD65 and the main titers were orders of magnitude higher than in IDDM patients. Furthermore, in contrast to the situation in IDDM, autoantibodies in 35 of 35 (100%) of SMS patients recognized denatured GAD65 on Western blots. Two major patterns of epitope specificity were identified on Western blots. The first pattern, detected in 25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with a linear NH2-terminal epitope residing in the first eight amino acids of GAD65. Nine of nine individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype and HLA-DR3, DQw2 was particularly abundant. The second pattern, detected in 10 of 35 patients (29%) of whom two had IDDM (20%), included reactivity with the NH2-terminal epitope plus strong reactivity with one or more additional epitope(s) residing COOH-terminal to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD65 molecule, but may also include some cases of epitope recognition associated with IDDM resistant HLA-haplotypes. The principal NH2-terminal linear epitope in GAD65 distinguishes the reactivity of SMS and IDDM autoantibodies and may be a determinant of pathogenicity for GABA-ergic neurons. The greater magnitude and distinct specificity of the humoral response to GAD65 in SMS may reflect a biased involvement of the T helper cell type 2 (Th2) subset of CD4+ T cells and antibody responses, whereas IDDM is likely mediated by the Th1 subset of CD4+ T cells and cytotoxic T cell responses.Keywords
This publication has 33 references indexed in Scilit:
- Differential Expression of GAD65 and GAD67 in Human, Rat, and Mouse Pancreatic IsletsDiabetes, 1993
- Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.Proceedings of the National Academy of Sciences, 1993
- Autoantibodies in IDDM Primarily Recognize the 65,000-Mr Rather Than 67,000-Mr Isoform of Glutamic Acid DecarboxylaseDiabetes, 1993
- Pancreatic beta cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble.Journal of Biological Chemistry, 1991
- Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic miceCell, 1991
- An Overview on Possible Mechanisms of Destruction of the Insulin-Producing Beta Cell1990
- Stiff-Man Syndrome UpdatedMayo Clinic Proceedings, 1989
- Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylaseThe Journal of Neuroscience, 1988
- Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.Journal of Clinical Investigation, 1987
- Monoclonal antibodies to glutamic acid decarboxylase.Proceedings of the National Academy of Sciences, 1986